Azenta, Inc. · NASDAQ:AZTA
Azenta — Q4 2026 Earnings Presentation
14 slides from Azenta's earnings presentation, Nov 11, 2026
Slide 1: Fiscal Fourth Quarter and Full Year 2026 Financial Results
Fiscal Fourth Quarter and Full Year 2026 Financial Results EARNINGS PRESENTATION November 11, 2026 © 2026 Azenta, Inc. • All rights reserved
Slide 2: Safe Harbor Statement
Safe Harbor Statement Safe Harbor Statement This presentation contains “forward-looking statements” made under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are neither promises nor guarantees but involve r
Slide 3: Positioned for Growth Entering Fiscal 2027
Positioned for Growth Entering Fiscal 2027 01 Q4 & FY’26 Performance 02 Multiomics Evolution FY’27 Outlook IMPROVING MOMENTUM BUILDING THE NEXT PHASE OF GENEWIZ ACCELERATING GROWTH AND PROFITABILITY Q4’26 Stronger foundation Organic revenue growth Revenue growth Leaner operations and optimized 3%–5%
Slide 4: Azenta Life Sciences Q4 & FY 2026 Financial Overview
Azenta Life Sciences Q4 & FY 2026 Financial Overview QUARTER AND FULL YEAR ENDED SEPTEMBER 30, 2026 Performance Highlights Revenue Adjusted Revenue • Q4’26 and FY’26 revenue increased 5% reported and 2% organically EBITDA Margin • SMS: 4% organic growth in Q4’26 and 2% in FY’26, led by Q4’26 FY'26 Q
Slide 5: Q4 2026 Selected Non-GAAP Financial Measures
Q4 2026 Selected Non-GAAP Financial Measures QUARTER ENDED SEPTEMBER 30, 2026 Organic Revenue Growth Segment Overview Sample Management Solutions • Sample Management Solutions up 4% 44% • High-teens growth in Sample Repository Multiomics Services (GENEWIZ) • $73M Revenue • Mid-teens growth in Consum
Slide 6: Summary Consolidated Balance Sheet
Summary Consolidated Balance Sheet AS OF SEPTEMBER 30, 2026 Balance Sheet $ millions Jun Sep 2026 2026 QtQ Cash, restricted cash, short term marketable securities 328 333 5 • $506M of cash, cash equivalents, restricted Accounts receivable, net 144 143 (0) Inventories 79 77 (2) cash and marketable se
Slide 7: Summary Consolidated Cash Flow
Summary Consolidated Cash Flow QUARTER ENDED SEPTEMBER 30, 2026 Cash Flow $ millions Q4'26 Cash, restricted cash and marketable securities - Beginning 529 Net income 7 • $506M of cash, cash equivalents, restricted Non-cash adjustments 1 cash and marketable securities Depreciation & amortization 15 •
Slide 8: Fiscal Year 2027 Guidance
Fiscal Year 2027 Guidance 2027 Guidance November 2026 Comments Reported: ~$648M–$660M Stronger commercial execution, improved pipeline and Organic: Up 3%–5% YoY backlog conversion, and better operational performance. Revenue Sample Management Solutions: +MSD The high-end of the revenue outlook inclu
Slide 9: Appendix
Appendix © 2026 Azenta, Inc. • All rights reserved
Slide 10: Q4 and Full Year 2026 Selected Non-GAAP Financial Measures
Q4 and Full Year 2026 Selected Non-GAAP Financial Measures QUARTER AND YEAR ENDED SEPTEMBER 30, 2026 Total Azenta Organic Revenue Growth $ millions except EPS and percentages $ millions Non-GAAP Non-GAAP Q4'25 Q4'26 YtY FY'25 FY'26 YtY Q4’25 Q4’26 YoY Revenue $ 159 $ 167 5% $ 594 $ 622 5% Reported 1
Slide 11: GAAP to Non-GAAP Reconciliation
GAAP to Non-GAAP Reconciliation CONTINUING OPERATIONS $ millions except per-share amounts and percentages Q1 F Y 25 Q2 F Y 25 Q3 F Y 25 Q4 F Y 25 F Y 25 Q1 F Y 26 Q2 F Y 26 Q3 F Y 26 Q4 F Y 26 F Y 26 Revenue 147.4 143.3 143.9 159.2 593.8 148.6 144.8 161.2 167.1 621.7 GAAP gross prof it 68.8 62.8 66.
Slide 12: GAAP to Non-GAAP Reconciliation - Segments
GAAP to Non-GAAP Reconciliation CONTINUING OPERATIONS – SEGMENTS $ millions except percentages Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 FY26 Multiomics Revenue 66.3 63.5 66.2 73.2 269.2 67.2 63.7 72.9 73.4 277.3 Gross profit 29.7 26.6 26.2 31.1 113.6 27.9 25.0 33.2 32.5 1
Slide 13: Net Income to Adjusted EBITDA Reconciliation
Net Income to Adjusted EBITDA Reconciliation CONTINUING OPERATIONS Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY25 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 FY26 $ millions except percentages Net income (11.0) (47.7) (48.0) 50.9 (55.8) (15.4) (160.8) 2.5 6.8 (167.0) (Income) Loss from discontinued operations, net of tax
Slide 14: Calculation of Non-GAAP Organic Revenue Growth
Calculation of Non-GAAP Organic Revenue Growth CONTINUING OPERATIONS Year-over-year % change Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 FY2025 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 FY2026 Revenue 4% 5% (0%) 6% 4% 1% 1% 12% 5% 5% Acquisitions/divestitures 0% 0% 0% 0% 0% 0% (1%) (3%) (3%) (2%) Currency exchange rates